Aligos Therapeutics, Inc.ALGSNASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank43
Studio
Year-over-Year Change

Year-over-year research & development expense growth

Percentile
P43
Within normal range
vs 5Y Ago
0x
Contraction
Streak
3 yr
Consecutive growthRecovering
PeriodValue
2025-1.16%
2024-3.79%
2023-14.15%
2022-18.32%
202130.37%
202081.41%
2019321.17%
20180.00%